Posts by Albert E. Kim, MD
-
Palbociclib Demonstrates Activity Against Progressive Brain Metastases Harboring CDK Pathway Alterations
A proof-of-concept study at the Massachusetts General Hospital Cancer Center showed genetic testing can guide treatment for patients with brain metastases from solid tumors, as 53% of patients with progressive brain metastases and CDK alterations showed benefit from palbociclib, a CDK inhibitor.
Biography
Albert E. Kim, MD, is an assistant in neurology at Massachusetts General Hospital and a physician investigator in the Cancer Center at the Mass General Research Institute. Dr. Kim is also an instructor in neurology at Harvard Medical School.
Mass General Brigham Cancer Institute
Mass General Brigham Cancer Institute unites leading experts and resources across our academic medical centers, making it one of the nation’s top providers of cancer care.